Αρχική World News Neoadjuvant Nivolumab Plus Ipilimumab Shows Trend Towards Long-Term Clinical Benefit versus Chemotherapy... World News Neoadjuvant Nivolumab Plus Ipilimumab Shows Trend Towards Long-Term Clinical Benefit versus Chemotherapy in Patients with Resectable NSCLC Από Ogkologos - 24 Φεβρουαρίου, 2025 947 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 816 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ EMA recommends granting a marketing authorisation for daraxonrasib Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? MOST POPULAR Cancer Surgery Unexpectedly Canceled for Mother of Two, Who Says It’s... 31 Μαρτίου, 2020 New Device Could “Hear” Stiffening of Extracellular Matrix to Determine Where... 2 Απριλίου, 2020 Treatment for Oropharyngeal Cancer: Investigating Ways to Do Less Harm 20 Μαΐου, 2021 Breast Cancer Patient Is Accused of Having “Body Image Issues” After... 5 Μαρτίου, 2021 Φόρτωση περισσοτέρων HOT NEWS EMA Recommends Granting a Marketing Authorisation for Relugolix EMA Recommends Extending Indications for Lisocabtagene Maraleucel New Risk Model Aims to Reduce Breast Cancer Disparities in Black... In Mouse Study, KRAS-Targeted Drug Shows Potential against Pancreatic Cancer